New Jersey Assembly Bill A1534

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Establishes Prescription Drug Review Commission; requires production costs be reported for certain prescription drugs.

Impact

The bill seeks to tackle the issue of excessive prescription drug prices in New Jersey by allowing the commission to set maximum allowable prices for drugs deemed overpriced. This action is expected to significantly impact the state's healthcare landscape by potentially lowering costs for consumers and public health programs, as prices will be aligned with those in other states and countries. In addition, the commission will prepare annual reports detailing the role of prescription drug prices in state healthcare spending and recommending actions to reduce costs while maintaining quality care.

Summary

Assembly Bill A1534 proposes the establishment of the Prescription Drug Review Commission within the Division of Consumer Affairs, under the Department of Law and Public Safety. This commission will be responsible for scrutinizing the costs associated with critical prescription drugs. Manufacturers will be required to provide detailed reports on their production costs, including research, development, and marketing expenses, aimed at ensuring transparency and accountability in drug pricing.

Contention

Despite its potential benefits, A1534 faces contention primarily from pharmaceutical manufacturers who may view the imposition of maximum prices as an infringement on their pricing freedom and a challenge to the economic models they currently rely on. Opponents may argue that this regulation could discourage innovation and development in pharmaceuticals, as reduced profitability might deter investments in new drugs. Additionally, there are concerns regarding the commission's authority and the balancing of interests between public health and the pharmaceutical industry.